Navigation Links
Monogram Announces Conference Call



SOUTH SAN FRANCISCO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) announced that it will hold a conference call on Monday, October 27, 2008 at 4:30 p.m. (Eastern Time) to discuss the clinical use of Monogram's Trofile(TM) Assay in conjunction with Pfizer's CCR5 antagonist, Selzentry(TM). Monogram will also review its third quarter 2008 financial results. The call will be hosted by William D. Young, Chairman & CEO of Monogram. Dr. David Hardy will participate in the call. Dr. Hardy is Director, Division of Infectious Diseases at Cedars-Sinai Medical Center and is Associate Professor of Medicine-in-Residence at the David Geffen School of Medicine at UCLA.

To participate in the live teleconference, please call (877) 604-9672, or (719) 325-4896 for international callers, fifteen minutes before the conference begins. Live audio of the call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. Access to live and archived audio of the conference call will be available on the Investor Relations section at Following the live broadcast, a replay of the call will also be available at (888) 203-1112 or (719) 457-0820 for international callers, through Sunday, November 9, 2008. The replay passcode is 4461917. The information provided on the teleconference is only accurate at the time of the conference call, and Monogram will take no responsibility for providing updated information except as required by law.

About Monogram Biosciences, Inc.

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at

Trofile is a trademark of Monogram Biosciences, Inc. Selzentry is a trademark of Pfizer Inc.

contacts: Alfred G. Merriweather Jeremiah Hall

Chief Financial Officer Feinstein Kean Healthcare

Tel: 650 624-4576 Tel: 415 677-2700

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Receives NASDAQ Notification
2. Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
3. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
4. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
5. Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
6. Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
7. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
8. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
9. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
10. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
11. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary ... in their initial angel funding process. Now, they are paying it forward to ... early stage investments in the microbiome space. In this, they join other ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... speaking at the following conference, and invited investors to ... NY      Tuesday, December 1, 2015 at 11.00 ... NY      Tuesday, December 1, 2015 at 11.00 ... Conference, New York, NY      Tuesday, ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
(Date:11/24/2015)... -- Clintrax Global, Inc., a worldwide provider of clinical research services headquartered ... the company has set a new quarterly earnings record in Q3 ... posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , with ...
Breaking Biology Technology:
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... the explosion of technology-enabled health and wellness, and the ... book, The Internet of Healthy Things ... or smartphones even existed, Dr. Kvedar, vice president, Connected ... health care delivery, moving care from the hospital or ...
Breaking Biology News(10 mins):